Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
Status:
Terminated
Trial end date:
2020-04-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well combination chemotherapy and inotuzumab ozogamicin work
in treating patients with B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as
cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate
and cytarabine, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with monoclonal antibodies, such as inotuzumab ozogamicin, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Giving combination chemotherapy and inotuzumab ozogamicin may work better at treating B acute
lymphoblastic leukemia.